Nicholas Wealth LLC. Has $898,000 Stock Holdings in Hims & Hers Health, Inc. $HIMS

Nicholas Wealth LLC. grew its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 67.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,265 shares of the company’s stock after purchasing an additional 17,397 shares during the period. Nicholas Wealth LLC.’s holdings in Hims & Hers Health were worth $898,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of HIMS. BAM Wealth Management LLC lifted its stake in Hims & Hers Health by 5.6% during the fourth quarter. BAM Wealth Management LLC now owns 7,380 shares of the company’s stock valued at $240,000 after buying an additional 393 shares in the last quarter. Xponance Inc. increased its position in shares of Hims & Hers Health by 1.5% in the third quarter. Xponance Inc. now owns 28,195 shares of the company’s stock worth $1,599,000 after acquiring an additional 419 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Hims & Hers Health by 3.1% in the second quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock worth $728,000 after acquiring an additional 443 shares in the last quarter. Sherman Porfolios LLC raised its holdings in shares of Hims & Hers Health by 10.5% during the third quarter. Sherman Porfolios LLC now owns 4,934 shares of the company’s stock valued at $280,000 after acquiring an additional 467 shares during the period. Finally, Binnacle Investments Inc acquired a new stake in shares of Hims & Hers Health during the third quarter valued at approximately $28,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on HIMS. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research note on Friday, May 22nd. Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $25.00 target price on shares of Hims & Hers Health in a report on Tuesday, May 5th. Truist Financial raised their target price on Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 22nd. Finally, Citigroup lifted their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. Four equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $29.37.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $33.86 on Friday. The company’s 50 day moving average price is $27.94 and its 200 day moving average price is $26.47. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a market capitalization of $7.84 billion, a PE ratio of -376.27, a PEG ratio of 48.52 and a beta of 2.37. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The firm’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.20 EPS. Research analysts expect that Hims & Hers Health, Inc. will post 0.05 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David B. Wells acquired 48,400 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the transaction, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Soleil Boughton sold 9,463 shares of the business’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the completion of the transaction, the insider owned 299,368 shares in the company, valued at $8,981,040. This trade represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 163,973 shares of company stock valued at $4,859,194 in the last three months. Company insiders own 11.76% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Investors are focusing on Hims’ growing obesity-drug opportunity as more employers cut coverage for expensive GLP-1 weight-loss drugs, potentially steering more patients toward cash-pay telehealth options. Hims’ obesity drug business may get boost as employers drop coverage
• Positive Sentiment: Novo Nordisk described Hims & Hers as one of its most “voluminous” telehealth partners, reinforcing confidence that the company is seeing meaningful demand tied to its weight-loss offering. HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
• Positive Sentiment: Commentary on Hims’ subscriber growth highlighted 2.6 million subscribers in Q1, up 9% year over year, suggesting the core business continues to expand. HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners
• Neutral Sentiment: Multiple valuation articles comparing Hims & Hers with Omnicell (OMCL) frame HIMS as a potential value stock, but they do not appear to introduce a clear new catalyst. OMCL or HIMS: Which Is the Better Value Stock Right Now?
• Negative Sentiment: A Seeking Alpha piece downgraded the stock, arguing that fundamentals may not fully support the recent rebound, which could temper bullish sentiment. Hims & Hers: Can Fundamentals Really Support This Rebound Rally? (Downgrade)
• Negative Sentiment: Recent insider selling by Patrick Harrison Carroll may add a small overhang for investors watching management and insider confidence. Patrick Harrison Carroll Sells 23,726 Shares of Hims & Hers Health (NYSE:HIMS) Stock

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.